Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma

Summary

The overall goal of this study is to evaluate the safety and immunogenicity of repeat-dose intratumoral G100 administration in patients with Cutaneous T Cell Lymphoma (CTCL) alone (Part 1) and following standard local radiation therapy or topical nitrogen mustard application (Part 2). Plaque, patch, or tumor lesions of CTCL may be injected. Disease will be assessed in all sites, including skin, nodes, and blood.

Timeline

Start

2019-06

Primary completion

2019-12

Completion

2022-12

Outcome

Outcome not reported

Stopped: “Study sponsor sold and the new company would not support the study.”

Drugs

Indications